SecBot SecBot
144 ·Filed Jun 26, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001969223-26-000725
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The Form 144 filing by CEO Grant Pickering is a routine advance notice of intent to sell a modest number of shares relative to the company's $8.1B market cap. The proposed sale (~$1.30M) is consistent with normal portfolio diversification and does not signal distress. Monitor for actual Form 4 filings to confirm execution, but no immediate trading action is warranted.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$57.72
T+0 close · Jun 26, 2026 · via day close
Latest settled
+2.25%
T+60 · $59.02
Vs SPY
−2.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $57.72entry
  2. T+1 · 5mo ago +0.71%α −0.07% · $58.13
  3. T+5 · 4mo ago −1.32%α −2.70% · $56.96
  4. T+20 · 4mo ago −5.30%α −5.02% · $54.66
  5. T+60 · 8w ago +2.25%α −2.13% · $59.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Grant Pickering filed a Form 144 notice of intent to sell 24,237 shares of Vaxcyte (PCVX) with an approximate market value of $1.30M, alongside 2,000 additional shares from family trusts. The filing signals insider selling intent but is a routine diversification move by the CEO, not a distress signal, given the company's $8.1B market cap and strong institutional backing.

Key Facts

  • CEO Grant Pickering filed Form 144 to sell 24,237 shares of Vaxcyte common stock, valued at approximately $1.30M based on the filing date.
  • An additional 2,000 shares are being sold via family trusts (Claire Pickering 2020 Delaware Trust and Benjamin Pickering 2020 Delaware Trust), each valued at ~$52,500.
  • The shares to be sold were acquired through RSU vesting (2023-2025), founder shares (2013), and prior RSU vesting (2024).
  • The filing is an advance notice of intent to sell, not a completed transaction, the sale may not occur.
  • Recent insider activity (30d) shows 9 sells totaling $1.3M, consistent with routine insider selling patterns.

Financial Impact

CEO proposes to sell ~24,237 shares worth ~$1.30M, representing a small fraction of the $8.1B market cap and likely a small portion of the insider's total holdings.

dilution

Risk Factors

  • Insider selling could be misinterpreted by the market as a lack of confidence, though the amount is small relative to market cap.
  • The sale is not yet executed, the insider may choose not to sell, making the filing a non-event.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-000725
Document: 0001969223-26-000725-index.html0001969223-26-000725
Document: 0001969223-26-000725.txt0001969223-26-000725

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026